JP7071975B2 - オピオイド嗜癖を避けるための医薬組成物 - Google Patents

オピオイド嗜癖を避けるための医薬組成物 Download PDF

Info

Publication number
JP7071975B2
JP7071975B2 JP2019525911A JP2019525911A JP7071975B2 JP 7071975 B2 JP7071975 B2 JP 7071975B2 JP 2019525911 A JP2019525911 A JP 2019525911A JP 2019525911 A JP2019525911 A JP 2019525911A JP 7071975 B2 JP7071975 B2 JP 7071975B2
Authority
JP
Japan
Prior art keywords
pain
antibody
patient
ngf
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019525911A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535716A (ja
JP2019535716A5 (enExample
Inventor
キャサリン・ステーマン－ブリーン
ジョン・デイヴィス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2019535716A publication Critical patent/JP2019535716A/ja
Publication of JP2019535716A5 publication Critical patent/JP2019535716A5/ja
Application granted granted Critical
Publication of JP7071975B2 publication Critical patent/JP7071975B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2019525911A 2016-11-29 2017-11-28 オピオイド嗜癖を避けるための医薬組成物 Active JP7071975B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662427365P 2016-11-29 2016-11-29
US62/427,365 2016-11-29
PCT/US2017/063417 WO2018102294A1 (en) 2016-11-29 2017-11-28 A pharmaceutical composition for averting opioid addiction

Publications (3)

Publication Number Publication Date
JP2019535716A JP2019535716A (ja) 2019-12-12
JP2019535716A5 JP2019535716A5 (enExample) 2020-12-10
JP7071975B2 true JP7071975B2 (ja) 2022-05-19

Family

ID=60766150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019525911A Active JP7071975B2 (ja) 2016-11-29 2017-11-28 オピオイド嗜癖を避けるための医薬組成物

Country Status (18)

Country Link
US (2) US10736961B2 (enExample)
EP (1) EP3548082B1 (enExample)
JP (1) JP7071975B2 (enExample)
KR (1) KR20190090820A (enExample)
CN (1) CN110072549A (enExample)
AU (1) AU2017366870B2 (enExample)
BR (1) BR112019010331A2 (enExample)
CA (1) CA3045116A1 (enExample)
CL (1) CL2019001385A1 (enExample)
CO (1) CO2019005247A2 (enExample)
EA (1) EA201991283A9 (enExample)
IL (1) IL266640B (enExample)
MA (2) MA46951A (enExample)
MX (1) MX2019006013A (enExample)
MY (1) MY200701A (enExample)
PH (1) PH12019501087A1 (enExample)
WO (1) WO2018102294A1 (enExample)
ZA (1) ZA201902967B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839956A (zh) * 2018-08-10 2021-05-25 瑞泽恩制药公司 安全有效治疗膝和/或髋疼痛的药物组合物
US20250011408A1 (en) 2021-11-19 2025-01-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
EP4514849A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ME00226B (me) 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
RS53661B1 (sr) 2007-08-10 2015-04-30 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
KR101867279B1 (ko) 2010-10-06 2018-06-15 리제너론 파아마슈티컬스, 인크. 항―인터류킨―４ 수용체（ｉｌ－４ｒ） 항체를 함유하는 안정화된 제형

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov archive,History of Changes for Study: NCT02620020，2016年11月16日， (v4), https://clinicaltrials.gov/ct2/history/NCT02620020?V_4=View#StudyPageTop［検索日：２０２１年９月３日］
MODERN PHYSICIAN，2014年，Vol.34, No.3，p.305-313

Also Published As

Publication number Publication date
CN110072549A (zh) 2019-07-30
AU2017366870A1 (en) 2019-06-06
JP2019535716A (ja) 2019-12-12
PH12019501087A1 (en) 2019-08-19
US10736961B2 (en) 2020-08-11
US20180147280A1 (en) 2018-05-31
US20210060159A1 (en) 2021-03-04
MA45890A1 (fr) 2020-02-28
KR20190090820A (ko) 2019-08-02
MA45890B2 (fr) 2022-10-31
EP3548082B1 (en) 2024-05-15
MY200701A (en) 2024-01-11
EA201991283A1 (ru) 2019-09-30
EP3548082A1 (en) 2019-10-09
CA3045116A1 (en) 2018-06-07
EA201991283A9 (ru) 2019-11-27
WO2018102294A1 (en) 2018-06-07
IL266640A (en) 2019-07-31
CL2019001385A1 (es) 2019-07-26
US11491222B2 (en) 2022-11-08
ZA201902967B (en) 2024-10-30
AU2017366870B2 (en) 2024-09-19
BR112019010331A2 (pt) 2019-10-22
IL266640B (en) 2022-09-01
MA46951A (fr) 2019-10-09
MX2019006013A (es) 2019-10-14
CO2019005247A2 (es) 2019-05-31

Similar Documents

Publication Publication Date Title
JP5537740B2 (ja) Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
US11491222B2 (en) Method of treating lower back pain
TW202239767A (zh) 用於治療類風濕性關節炎之組成物及方法
US20220041708A1 (en) Pharmaceutical Composition for Safe and Effective Treatment of Knee and/or Hip Pain
KR20210122810A (ko) 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
AU2024202601A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
RU2786232C2 (ru) Фармацевтическая композиция для безопасного и эффективного лечения боли колена и/или тазобедренного сустава
EA044062B1 (ru) Фармацевтическая композиция для предотвращения опиоидной зависимости
US20250011408A1 (en) Methods and compositions for reducing centralized pain
HK40011843A (en) A pharmaceutical composition for averting opioid addiction
WO2022197782A1 (en) Methods of treating atopic dermatitis with anti il-13 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220311

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220509

R150 Certificate of patent or registration of utility model

Ref document number: 7071975

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250